Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
Disc Medicine released its Q2 2026 financial results and business updates, highlighting progress in its hematologic disease drug pipeline. Key milestones include completion of Phase 3 enrollment and FDA alignment on bitopertin's APOLLO trial in erythropoietic protoporphyria, enrollment completion and upcoming data for DISC-3405 in polycythemia vera…